VYNE THERAPEUTICS INC (VYNE)
US92941V3087 - Common Stock
VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting
Presentations will highlight positive preclinical and Phase 1b data of novel BET inhibitor, VYN201, in nonsegmental vitiligo BRIDGEWATER, N.J., May 01,...
VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update
2023 was a transformative year for VYNE, marked by the achievement of clinical proof-of-concept for VYN201 in vitiligo and a successful financing with a...
VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
BRIDGEWATER, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time to dive into the biggest pre-market stock movers for Thursday as we check out all of the hottest news this morning!
Vyne reports positive data from Phase 1b study for vitiligo drug (NASDAQ:VYNE)
Vyne Therapeutics (VYNE) reported positive Phase 1b biomarker data for its vitiligo drug candidate VYN201. Read more here.
VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors
BRIDGEWATER, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical...
VYNE Therapeutics says director Lepore buys 13K shares in co (NASDAQ:VYNE)
Patrick Lepore, CEO of VYNE Therapeutics, buys 13K shares at $3.90 each. Net sale activity in the past three months was 12K shares.
VYNE Therapeutics files to sell 36.27M shares for holders (NASDAQ:VYNE)
VYNE Therapeutics files prospectus for the proposed resale of 39.27M shares by selling shareholders. This is not an offer to sell securities.
VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
Transformative capital raise of $88.2 million from leading healthcare investors provides funding for BET inhibitor programs through the end of 2025
VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million
Transformative capital raise to fund VYNE’s BET inhibitor programs through the end of 2025...
Vyne Therapeutics jumps 52% on $88M private placement (NASDAQ:VYNE)
Clinical-stage biopharmaceutical company VYNE Therapeutics (VYNE) surged 52% to $2.90 per share on MOnday pre-market as the company signed a $88M securities purchase agreement
VYNE Therapeutics Reports Positive Results from Preclinical Models for Oral BD2-Selective BET Inhibitor VYN202
Treatment with VYN202 resulted in significant inhibition of key inflammatory biomarkers and substantial resolution of the signs and symptoms of psoriasis...
VYNE Therapeutics Announces Private Placement of $88 Million
Transaction provides $88 million to fund VYNE’s clinical development programs for VYN201 and VYN202 through the end of 2025...
VYNE Therapeutics Announces Positive Data from Phase 1b Trial for Novel BET Inhibitor VYN201 in Patients with Nonsegmental Vitiligo
Clinical proof-of-concept achieved with statistically significant dose dependent reduction in F-VASI score from baseline for the VYN201 1.0% and 2.0%...
VYNE Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
Anticipate announcing preliminary Phase 1b safety and efficacy data for pan-BD BET inhibitor, VYN201, in nonsegmental vitiligo in Q3 2023 ...
VYNE Therapeutics to Attend BIO International Convention
BRIDGEWATER, N.J., May 18, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical...
VYNE Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
Anticipate topline 16-week data for all three cohorts from the Phase 1b trial for pan-BD BET inhibitor, VYN201, in nonsegmental vitiligo in the third...
VYNE Therapeutics Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory Conditions
Preclinical studies suggest VYN202 has the potential to be the most potent and selective BET inhibitor in development VYN202 has demonstrated a potent...